Top Page
Valneva
(NASDAQ:VALN)
Valneva (VALN) vs. SPDR S&P 500 ETF (SPY)
Valneva Business Overview & Revenue Model
Valneva Earnings Call Summary
Valneva Financial Statement Overview
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Valneva Technical Analysis
Valneva Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | ― | ― | ― | ― | ― | ― | |
61 Neutral | $1.61B | -16.11 | -64.93% | ― | -36.36% | -945.72% | |
50 Neutral | $1.10B | -6.76 | ― | ― | 8.00% | -10.15% | |
49 Neutral | $907.77M | -21.10 | -45.88% | ― | 116.64% | 47.93% | |
48 Neutral | $746.84M | -6.10 | -54.42% | ― | 14.86% | -1440.45% | |
44 Neutral | $851.21M | -1.07 | ― | ― | -12.52% | -82.84% | |
33 Underperform | $1.22B | -4.67 | -96.11% | ― | ― | 31.16% |
Valneva Corporate Events
On November 26, 2025, Valneva SE announced a strategic initiative to consolidate its operations in France, focusing its activities at the Lyon site and closing its Nantes location to streamline operations and improve efficiency. This move is part of Valneva’s efforts to enhance operational effectiveness and position itself for long-term success. The consolidation will also centralize all R&D activities in Vienna. The company is committed to supporting its employees during this transition, ensuring a smooth process for all affected team members.
On November 26, 2025, Valneva SE announced its financial results for the first nine months of 2025, reporting total revenues of €127.0 million, an 8.9% increase from the previous year. Despite a net loss of €65.2 million, the company achieved significant financial flexibility through successful debt refinancing and reduced operating cash burn. Valneva’s Lyme disease vaccine candidate, VLA15, is progressing well in its Phase 3 study, with results expected in 2026. The company also highlighted the growth in sales of its Japanese encephalitis vaccine and the launch of its chikungunya vaccine, IXCHIQ®, despite regulatory challenges in the U.S.
On November 20, 2025, Valneva SE reported its financial results for the first nine months of 2025, highlighting an 8.9% increase in total revenues to €127.0 million compared to the same period in 2024. The company achieved significant financial flexibility through successful debt refinancing and reduced operating cash burn. Despite a net loss of €65.2 million, Valneva’s commercial portfolio showed growth, particularly in its Japanese encephalitis vaccine sales. The company is advancing its Lyme disease vaccine candidate with Pfizer, expecting Phase 3 results in 2026, and is also progressing with its Shigella vaccine candidate, which received Fast Track designation from the FDA.
Valneva SE announced positive results from its Phase 1 clinical trial of VLA1601, a second-generation adjuvanted inactivated vaccine candidate against the Zika virus. Conducted in the United States with approximately 150 participants, the trial demonstrated that VLA1601 was generally safe and well tolerated, with no safety concerns identified. The strongest immune response was observed in the double-adjuvant treatment arms, showing significantly higher neutralizing antibody titers compared to the single-adjuvant arm. These results indicate an improved immune response over the first-generation vaccine candidate, but further development will depend on securing major funding opportunities.
On October 6, 2025, Valneva SE announced a new $500 million non-dilutive financing agreement with Pharmakon Advisors, LP, which includes an initial tranche of $215 million to refinance existing debt. This agreement enhances Valneva’s financial flexibility by lowering the cost of capital and extending repayment terms, allowing the company to focus on advancing its vaccine pipeline, including the Lyme disease candidate VLA15. Additionally, Valneva adjusted its 2025 financial guidance due to the FDA’s suspension of the IXCHIQ® product license, expecting lower product sales and total revenues. The company remains on track with its Phase 3 clinical trial for the Lyme disease vaccine, with outcomes expected in the first half of 2026 and potential commercialization by Pfizer in 2027.
On September 30, 2025, Valneva SE announced positive four-year antibody persistence data for its chikungunya vaccine, IXCHIQ®. The data showed that 95% of participants maintained neutralizing antibody titers above the seroresponse threshold, with similar results across different age groups. This long-lasting antibody persistence is a significant advantage for the vaccine, especially in areas prone to chikungunya outbreaks. The trial, supported by CEPI and the EU’s Horizon Europe program, also reported no safety concerns. Valneva aims to expand vaccine access, particularly in low- and middle-income countries, through partnerships such as the one with the Serum Institute of India.